TextAE configuration unavailable!

PubMed:31610337 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id	Subject	Object	Predicate	Lexical cue
T1	0-146	Sentence	denotes	No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis.
T2	147-165	Sentence	denotes	BACKGROUND & AIMS:
T3	166-340	Sentence	denotes	Ulcerative proctitis (UP) refractory to 5-aminosalicylic acid (5-ASA) suppositories is a challenge to treat, often requiring step up to immunomodulator or biological therapy.
T4	341-413	Sentence	denotes	Topical tacrolimus is effective and safe in patients with refractory UP.
T5	414-510	Sentence	denotes	However, it is not clear how tacrolimus suppositories fit into in the treatment algorithm of UP.
T6	511-519	Sentence	denotes	METHODS:
T7	520-646	Sentence	denotes	We performed a randomized controlled, double-blind study at 8 hospitals in the Netherlands and Belgium from 2014 through 2017.
T8	647-834	Sentence	denotes	Eighty-five patients with refractory UP (65% women) were randomly assigned to groups given once daily tacrolimus suppositories (2 mg; n = 43) or beclomethasone (3 mg; n = 42) for 4 weeks.
T9	835-915	Sentence	denotes	The primary outcome was clinical response (decrease in Mayo score of 3 or more).
T10	916-1034	Sentence	denotes	Secondary outcomes included clinical remission, endoscopic response and remission, adverse events and quality of life.
T11	1035-1108	Sentence	denotes	Outcomes were compared using Fisher's exact test and Mann-Whitney U test.
T12	1109-1117	Sentence	denotes	RESULTS:
T13	1118-1335	Sentence	denotes	Proportions of patients with clinical responses were 63% in the tacrolimus group and 59% in the beclomethasone group (P = .812); proportions of patients in clinical remission were 46% and 38%, respectively (P = .638).
T14	1336-1710	Sentence	denotes	Proportions of patients with an endoscopic response were 68% and 60% in the tacrolimus group and in the beclomethasone group (P = .636); proportions in endoscopic remission rates were 30% and 13%, respectively (P = .092) Median increases in the inflammatory bowel disease questionnaire score were 18.0 in the tacrolimus group and 20.5 in the beclomethasone group (P = .395).
T15	1711-1775	Sentence	denotes	Adverse event rates did not differ significantly between groups.
T16	1776-1788	Sentence	denotes	CONCLUSIONS:
T17	1789-1966	Sentence	denotes	In a 4-week randomized controlled trial, tacrolimus and beclomethasone suppositories induce comparable clinical and endoscopic responses in patients with UP refractory to 5-ASA.
T18	1967-2029	Sentence	denotes	There were no significant differences in adverse events rates.
T19	2030-2159	Sentence	denotes	Tacrolimus and beclomethasone suppositories are therefore each safe and effective treatment options for 5-ASA refractory disease.
T20	2160-2226	Sentence	denotes	EUDRACT 2013-001259-11; Netherlands Trial Register NL4205/NTR4416.
T1	0-146	Sentence	denotes	No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis.
T2	147-165	Sentence	denotes	BACKGROUND & AIMS:
T3	166-340	Sentence	denotes	Ulcerative proctitis (UP) refractory to 5-aminosalicylic acid (5-ASA) suppositories is a challenge to treat, often requiring step up to immunomodulator or biological therapy.
T4	341-413	Sentence	denotes	Topical tacrolimus is effective and safe in patients with refractory UP.
T5	414-510	Sentence	denotes	However, it is not clear how tacrolimus suppositories fit into in the treatment algorithm of UP.
T6	511-519	Sentence	denotes	METHODS:
T7	520-646	Sentence	denotes	We performed a randomized controlled, double-blind study at 8 hospitals in the Netherlands and Belgium from 2014 through 2017.
T8	647-834	Sentence	denotes	Eighty-five patients with refractory UP (65% women) were randomly assigned to groups given once daily tacrolimus suppositories (2 mg; n = 43) or beclomethasone (3 mg; n = 42) for 4 weeks.
T9	835-915	Sentence	denotes	The primary outcome was clinical response (decrease in Mayo score of 3 or more).
T10	916-1034	Sentence	denotes	Secondary outcomes included clinical remission, endoscopic response and remission, adverse events and quality of life.
T11	1035-1108	Sentence	denotes	Outcomes were compared using Fisher's exact test and Mann-Whitney U test.
T12	1109-1117	Sentence	denotes	RESULTS:
T13	1118-1335	Sentence	denotes	Proportions of patients with clinical responses were 63% in the tacrolimus group and 59% in the beclomethasone group (P = .812); proportions of patients in clinical remission were 46% and 38%, respectively (P = .638).
T14	1336-1710	Sentence	denotes	Proportions of patients with an endoscopic response were 68% and 60% in the tacrolimus group and in the beclomethasone group (P = .636); proportions in endoscopic remission rates were 30% and 13%, respectively (P = .092) Median increases in the inflammatory bowel disease questionnaire score were 18.0 in the tacrolimus group and 20.5 in the beclomethasone group (P = .395).
T15	1711-1775	Sentence	denotes	Adverse event rates did not differ significantly between groups.
T16	1776-1788	Sentence	denotes	CONCLUSIONS:
T17	1789-1966	Sentence	denotes	In a 4-week randomized controlled trial, tacrolimus and beclomethasone suppositories induce comparable clinical and endoscopic responses in patients with UP refractory to 5-ASA.
T18	1967-2029	Sentence	denotes	There were no significant differences in adverse events rates.
T19	2030-2159	Sentence	denotes	Tacrolimus and beclomethasone suppositories are therefore each safe and effective treatment options for 5-ASA refractory disease.
T20	2160-2226	Sentence	denotes	EUDRACT 2013-001259-11; Netherlands Trial Register NL4205/NTR4416.